Last Close
Apr 08  •  04:00PM ET
172.54
Dollar change
+1.92
Percentage change
1.13
%
Index
S&P 500
P/E
21.96
EPS (ttm)
7.86
Insider Own
0.96%
Shs Outstand
169.60M
Perf Week
1.17%
Market Cap
29.28B
Forward P/E
12.26
EPS next Y
14.07
Insider Trans
-5.63%
Shs Float
168.07M
Perf Month
-3.37%
Enterprise Value
43.53B
PEG
1.28
EPS next Q
2.82
Inst Own
100.48%
Perf Quarter
-28.27%
Income
1.36B
P/S
1.80
EPS this Y
6.54%
Inst Trans
2.00%
Perf Half Y
-15.84%
Sales
16.30B
P/B
4.50
EPS next Y
10.80%
ROA
4.79%
Perf YTD
-23.46%
Book/sh
38.34
P/C
13.68
EPS next 5Y
9.58%
ROE
21.64%
52W High
247.04 -30.16%
Perf Year
19.41%
Cash/sh
12.62
P/FCF
14.28
EPS past 3/5Y
11.05% 40.52%
ROIC
6.53%
52W Low
134.65 28.14%
Perf 3Y
-11.89%
Dividend Est.
-
EV/EBITDA
12.71
Sales past 3/5Y
4.18% 7.50%
Gross Margin
26.25%
Volatility
3.82% 3.71%
Perf 5Y
-15.56%
Dividend TTM
-
EV/Sales
2.67
EPS Y/Y TTM
4.62%
Oper. Margin
13.99%
ATR (14)
6.79
Perf 10Y
143.60%
Dividend Ex-Date
-
Quick Ratio
0.75
Sales Y/Y TTM
5.84%
Profit Margin
8.34%
RSI (14)
50.49
Dividend Gr. 3/5Y
- -
Current Ratio
0.75
EPS Q/Q
23.71%
SMA20
2.69%
Beta
1.32
Payout
0.00%
Debt/Eq
2.50
Sales Q/Q
10.13%
SMA50
-3.49%
Rel Volume
0.85
Prev Close
170.62
Employees
93000
LT Debt/Eq
2.20
SMA200
-12.12%
Avg Volume
2.07M
Price
172.54
IPO
May 09, 2013
Option/Short
Yes / Yes
Trades
Volume
1,756,696
Change
1.13%
Date Action Analyst Rating Change Price Target Change
Mar-09-26Upgrade TD Cowen Hold → Buy $213
Mar-06-26Upgrade Barclays Equal Weight → Overweight $210
Mar-03-26Initiated RBC Capital Mkts Outperform $221
Dec-02-25Resumed Morgan Stanley Overweight $265
Nov-13-25Initiated BMO Capital Markets Outperform $260
Nov-03-25Downgrade TD Cowen Buy → Hold $215
Oct-29-25Upgrade Robert W. Baird Neutral → Outperform $258
Oct-09-25Upgrade HSBC Securities Hold → Buy $235
Sep-09-25Upgrade Jefferies Hold → Buy $225
Apr-25-25Downgrade HSBC Securities Buy → Hold $160
Mar-16-26 04:30PM
Mar-10-26 02:38PM
10:01AM
Mar-09-26 09:33AM
Mar-04-26 10:08AM
09:33AM Loading…
Mar-03-26 09:33AM
Mar-02-26 04:30PM
04:15PM
12:13PM
Mar-01-26 04:24AM
Feb-27-26 04:47PM
Feb-26-26 11:53PM
09:03AM
06:42AM
Feb-25-26 11:08PM
09:06AM Loading…
09:06AM
07:00AM
Feb-24-26 02:33PM
Feb-21-26 10:39AM
Feb-19-26 10:36AM
05:38AM
Feb-18-26 04:15PM
09:15AM
Feb-17-26 11:46AM
Feb-13-26 08:32AM
Feb-12-26 12:30PM
12:36AM
Feb-11-26 07:19PM
Feb-10-26 08:00AM
Feb-08-26 08:39AM
07:21PM Loading…
Feb-06-26 07:21PM
09:40AM
12:54AM
12:35AM
Feb-05-26 04:00PM
12:11PM
11:55AM
09:07AM
08:15AM
07:36AM
07:20AM
07:00AM
Feb-04-26 11:40AM
Feb-03-26 10:14PM
11:23AM
09:15AM
Jan-29-26 08:00AM
Jan-25-26 11:44AM
Jan-22-26 04:05PM
Jan-20-26 04:45PM
Jan-15-26 09:36AM
Jan-14-26 09:50AM
Jan-13-26 09:11AM
Jan-12-26 11:36PM
Jan-11-26 11:04PM
Jan-09-26 09:40AM
Dec-29-25 12:55PM
Dec-17-25 09:40AM
Dec-09-25 10:19AM
09:50AM
Dec-04-25 12:21PM
Dec-03-25 10:32PM
Dec-02-25 08:00AM
Nov-28-25 11:30AM
Nov-27-25 11:30AM
Nov-26-25 09:40AM
Nov-11-25 09:50AM
Nov-06-25 10:32PM
12:38PM
12:33PM
Nov-05-25 04:15PM
09:40AM
Nov-04-25 12:31AM
Nov-03-25 01:15PM
09:42AM
Oct-30-25 03:14PM
Oct-29-25 03:45PM
01:31AM
Oct-28-25 08:00PM
01:09PM
08:15AM
07:28AM
07:14AM
07:00AM
Oct-26-25 11:08PM
Oct-23-25 10:19AM
Oct-22-25 10:00AM
Oct-21-25 04:15PM
10:00AM
Oct-20-25 01:35PM
Oct-15-25 04:25AM
Oct-10-25 12:00AM
Oct-09-25 09:37AM
Oct-01-25 06:48PM
04:01PM
10:10AM
Sep-30-25 04:15PM
Sep-29-25 09:43AM
Sep-19-25 09:40AM
08:58AM
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOUSBIB ARISee RemarksDec 18 '25Option Exercise59.9050,0002,995,000857,163Dec 19 05:00 PM
BOUSBIB ARISee RemarksDec 18 '25Sale222.4336,5648,132,931820,599Dec 19 05:00 PM
ARI BOUSBIBOfficerDec 18 '25Proposed Sale222.4336,5648,132,876Dec 18 05:41 PM
Sherbet EricSee RemarksOct 29 '25Option Exercise131.8210,0001,318,20031,108Oct 31 05:01 PM
Sherbet EricSee RemarksOct 29 '25Sale219.704,000878,80027,108Oct 31 05:01 PM
BOUSBIB ARISee RemarksOct 29 '25Option Exercise59.9077,5924,647,761884,755Oct 31 05:00 PM
BOUSBIB ARISee RemarksOct 29 '25Sale220.3356,55712,461,119828,198Oct 31 05:00 PM
ARI BOUSBIBOfficerOct 29 '25Proposed Sale220.3356,55712,460,983Oct 29 04:18 PM
ERIC SHERBETOfficerOct 29 '25Proposed Sale219.704,000878,820Oct 29 04:10 PM
Cherofsky KeriannSee RemarksJul 23 '25Sale191.53549105,1502,910Jul 25 05:01 PM
Sherbet EricSee RemarksJul 23 '25Option Exercise97.2011,8701,153,76432,978Jul 25 05:00 PM
Sherbet EricSee RemarksJul 23 '25Sale190.055,8001,102,29027,178Jul 25 05:00 PM
ERIC SHERBETOfficerJul 23 '25Proposed Sale190.055,8001,102,262Jul 23 05:53 PM
KERIANN CHEROFSKYOfficerJul 23 '25Proposed Sale191.53549105,150Jul 23 04:01 PM